#United States #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense's Developments: Key Milestones on the Horizon

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is carving a path forward in the biotechnology landscape, striving to make a difference in the arena of neurodegenerative diseases. Recently, the company announced a hearing date with the Nasdaq Hearings Panel, scheduled for November 10, 2026. This move follows their appeal against an October 1 determination regarding potential delisting. By lodging this appeal, NeuroSense managed to halt any immediate suspension or delisting actions, ensuring that its shares continue trading under "NRSN" and its associated warrants under "NRSNW" until the Panel reaches a decision.

At the core of NeuroSense’s mission is PrimeC, a novel oral therapy aimed at tackling serious neurological conditions, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The recent trajectory of NeuroSense is punctuated by the recovery of compliance with Nasdaq's minimum bid price requirement. The company remains focused on addressing the last identified issue—a deficiency in meeting the $35 million minimum market value of listed securities requirement.

CEO's Insight

NeuroSense's CEO, Alon Ben-Noon, expressed optimism regarding the company's compliance strategy, outlining plans to showcase their approach to fulfill this requirement during the upcoming hearing. He emphasized that PrimeC's results from the Phase 2b clinical trial published in JAMA Neurology, along with FDA clearance to initiate the Phase 3 PARAGON trial, lay a robust foundation for advancing their development plans.

The forthcoming months are pivotal, with the New Drug Submission to Health Canada anticipated in December 2026. Concurrently, NeuroSense expects feedback regarding non-dilutive funding for the Phase 3 PARAGON trial by the first quarter of 2027, contingent upon the completion of the ongoing grant review.

Strategic Developments

The potential for non-dilutive funding is a welcome prospect for NeuroSense, as it could lessen reliance on the equity markets while providing necessary financial support for advancing PrimeC through clinical trials. This mixed funding strategy, coupled with ongoing strategic business development opportunities, could bolster NeuroSense's position in the market.

The Path Ahead

Despite the optimism, challenges remain, particularly regarding the remaining compliance deficiencies that the company plans to address at the hearing. To alleviate these issues, the Panel may grant NeuroSense an exception period, allowing them up to 180 days to implement their compliance strategy. However, these plans remain contingent on the Panel's decision, and there are no guarantees that an exception will be granted.

Upcoming Milestones

NeuroSense’s forward-looking agenda includes:

• - Finalizing the Health Canada New Drug Submission for PrimeC targeting ALS by December 2026.
• - Anticipating a decision on non-dilutive grant funding for the Phase 3 PARAGON trial in early 2027.

Understanding PrimeC

PrimeC is a unique therapeutic formulation that combines two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed-dose combination designed to combat key biological pathways responsible for neurodegeneration. The encouraging findings from the Phase 2b PARADIGM study, highlighting a slower functional decline in participants who received PrimeC, reaffirm the drug’s potential efficacy. Additionally, the observed changes in multiple biomarkers associated with ALS further underscore the therapeutic promise of PrimeC.

The Challenge of ALS

Amyotrophic lateral sclerosis (ALS) remains a formidable obstacle; this progressive neurodegenerative disease leads to paralysis and eventual mortality, typically within three years of symptom onset. With over 5,000 annual cases diagnosed in the U.S. alone and an expected increase in prevalence, the urgency for effective treatments is palpable. NeuroSense’s focus on PrimeC presents a beacon of hope for patients and families facing the devastating impact of ALS.

In conclusion, as NeuroSense Therapeutics navigates these critical next steps, industry stakeholders and investors alike will be keenly watching how the upcoming Nasdaq hearing unfolds and how the company executes its ambitious plans surrounding PrimeC. Through perseverance and innovation, NeuroSense aims not only to meet regulatory expectations but to deliver impactful treatments that may change the landscape of neurodegenerative disease management.